Delivery Order SPE2DB22D3004-SPE2DB24FQE95
Award Date
5/1/24
Potential Completion Date
5/2/24
Potential Value
$3.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $31,939.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $12,212.72, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of May 24, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The...
This federal contract award, valued at $2,942.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a performance period ending on December 5, 2024. The contract is a Delivery Order and is priced as a Firm Fixed Price. This award is not associated with a set-aside program. The contract is part...
This federal contract award, valued at $5,276.38, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The award is a delivery order contract for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of July 9, 2024 and is a firm fixed price agreement. This award is not associated with a set-aside designation. Amerisourcebergen Drug Corp, a major supplier of pharmaceutical...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $97,545.40, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This is a firm fixed-price delivery order contract with a completion date of February 28, 2025. The contract was awarded on February 27, 2025 and does not have a set-aside designation, indicating open...
This federal contract award, valued at $71,491.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of December 19, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $7,886.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. Amerisourcebergen, a major supplier of pharmaceutical products and medical supplies to the U.S. government, was awarded this firm fixed-price delivery order contract with a completion date of May 21, 2024. The company has a substantial...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,182.96, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The contract is a Delivery Order under a larger...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the provision of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $3,154.56, is a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which is valued up to $999,999,999.00 and runs through December 31, 2025. This single-award IDC serves as the primary...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $2,039.05 and a completion date of November 20, 2024. This is a delivery order contract with a firm fixed price pricing type. The award is not associated with a set-aside program. Amerisourcebergen Drug...